Drug manufacturer Aurobindo Pharma Limited on Monday said that, “it has closed the acquisition of Apotex’s commercial operations and certain supporting infrastructure in five European countries,” in a filing to Bombay Stock Exchange.
“The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on 14 July 2018,” the company said.
This announcement does not constitute a recommendation to shareholders or potential investors.
Jefferies International Limited acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.
The shares of the company were trading at 755.50 apiece, low at 5.15 points or 0.68 per cent at 12:05 hours on the BSE.